The Experts below are selected from a list of 3159 Experts worldwide ranked by ideXlab platform
Tobias Uller - One of the best experts on this subject based on the ideXlab platform.
-
genetic differentiation predicts body size divergence between island and mainland populations of common wall lizards podarcis muralis
Biological Journal of The Linnean Society, 2019Co-Authors: Geoffrey M. While, Tobias Uller, Sozos Michaelides, Hanna Laakkonen, Aurelie Coulon, Fabien AubretAbstract:Small-bodied vertebrates sometimes evolve Gigantism on islands, but there is a lack of consistent association with ecological factors or island characteristics. One possible reason is that, even if the ecological conditions are right, body size might fail to diverge on islands that were isolated recently or if there is gene flow between islands and the mainland. We studied body size, ventral colour polymorphism and genetic structure across nine islands and adjacent mainland populations of common wall lizards (Podarcis muralis) off the western coast of France. Population genetic data suggested that island populations might have maintained gene flow after their geographical isolation from the mainland. Island lizards were larger and heavier than mainland lizards on average, but the extent of Gigantism varied substantially between islands. Island size and distance from the mainland were poor predictors of body size, but lizards from populations that were highly genetically differentiated from the mainland were larger than lizards from less differentiated populations. Colour morphs that were rare on the mainland tended to be more common on islands. We propose that genetic isolation or bottlenecks promote body size evolution in island lizards, which makes it challenging to identify ecological causes of island Gigantism without complementary genetic information.
Ayala Blanco, Lucy Stephania - One of the best experts on this subject based on the ideXlab platform.
-
Análisis de impacto presupuestal para Octeotride, Lanreotide y Pasiotide en el tratamiento de la Acromegalia y Gigantismo en Colombia
'Elsevier BV', 2019Co-Authors: Sánchez Barreto Jakelin, Ayala Blanco, Lucy StephaniaAbstract:60 páginas : gráficasIn Colombia a disease orphan is recognized by law 1392 of 2010 and is defined as that chronically debilitating, serious, that threatens the life and with a lower prevalence of 1 per 5,000. One of the diseases that are facing this problem is the acromegaly and Gigantism due to their complexity in the diagnosis, with an annual incidence of three to four new cases per million inhabitants and prevalence between 40 and 90 cases per million and given its lines of treatment is considered of high cost. The development of new health technologies today allows to generate good resource management and strengthen the system. To carry out a budget impact analysis of some technology of interest it is necessary To manage the economic evaluations which will allow to support in the decision making in health worldwide. In Colombia, 1483 people are reported to be diagnosed with the pathologies of acromegaly and Gigantism. Somatostatin analogues have been studied in the treatment of acromegaly and Gigantism, it has been shown that they are highly effective in inhibiting growth hormone production. According to the guides consulted their effect and the duration of their action is much greater compared to the dopamine agonists as evidenced in the ranges and periods of dosage described above, as it requires a much greater amount of Bromocriptine in shorter periods of time. For the costs of Pasireotide is evidence that there is a maximum price or minimum standardized as the average of the data obtained through the institutional channel in the database of the SISMED, shows that the price of all suppliers this averaging and there is no overrun by any manufacturer. The use of these technologies allows an approach of cases where acromegaly is highly active and cannot be controlled and which in turn can be used in the treatment where the alteration of the growth hormone secretion is minimal. For the FOSYGA the result obtained makes it clear that if scenario 1 is applied to the deterministic level there will be a saving of about $10 million COP, in scenario number 2, the investment must be of about $600,000 COP, but it is necessary by the state Keep in mind that the effectiveness of the treatment in implementing the use of the three new technologies will be much greater. It is suggested that the technologies called (Octeotride, lanreotide and pasireotide) are included in the comprehensive plan of health, given that the cost makes it accessible to the populationEn Colombia una enfermedad huérfana es reconocida por la ley 1392 de 2010 y se define como aquella crónicamente debilitante, grave, que amenaza la vida y con una prevalencia menor de 1 por cada 5.000. Una de las enfermedades que se enfrentan a esta problemática es la Acromegalia y el Gigantismo debido a su complejidad en el diagnóstico, con una incidencia anual de tres a cuatro casos nuevos por millón de habitantes y prevalencia entre 40 y 90 casos por millón y dadas sus líneas de tratamiento se considera de alto costo. El desarrollo de nuevas tecnologías de salud en la actualidad permite generar una buena administración de recursos y fortalecer el sistema. Para realizar un análisis de impacto en presupuesto de alguna tecnología de interés es preciso gestionar las evaluaciones económicas las cuales permitirán apoyar en la toma de decisiones en salud a nivel mundial. En Colombia se encuentran reportadas 1483 personas que son diagnosticados con las patologías de acromegalia y Gigantismo. Los análogos de somatostatina han sido estudiados en el tratamiento de la acromegalia y Gigantismo, se ha evidenciado que son altamente eficaces en la inhibición de producción de la hormona de crecimiento. De acuerdo con las guías consultadas su efecto y la duración de su acción es mucho mayor en comparación a los agonistas dopaminérgicos como se evidencia en los rangos y periodos de dosificación anteriormente descritos, ya que se requiere una cantidad mucho mayor de Bromocriptina en periodos más cortos de tiempo. Para los costos del Pasireotide se evidencia que no hay un precio máximo o mínimo estandarizado ya que el promedio de los datos obtenidos a través del canal institucional en la base de datos del SISMED, muestra que el precio de todos los proveedores esta promediado y no hay un sobrecosto por parte de algún fabricante. El uso de estas tecnologías permite un abordaje de casos donde la acromegalia es altamente activa y no se puede controlar y que a su vez puedan ser utilizados en el tratamiento donde la alteración de la secreción de hormona de crecimiento es mínima. Para el FOSYGA el resultado obtenido permite evidenciar que si se aplica el escenario 1 a nivel determinístico habrá un ahorro de cerca de $10.000.000 COP, en un escenario número 2, la inversión debe ser de alrededor de $600.000 COP, pero es necesario por parte del estado tener en cuenta que la efectividad del tratamiento al implementar el uso de las tres nuevas tecnologías será mucho mayor. Se sugiere que las tecnologías denominadas (Octreotide, Lanreotide y Pasireotide) sean incluidas en el plan integral de salud, dado que el costo hace que sea accesible a la población.Incluye bibliografíaPregradoQuímico(a) Farmacéutic
-
Análisis de impacto presupuestal para Octeotride, Lanreotide y Pasiotide en el tratamiento de la Acromegalia y Gigantismo en Colombia
Bogotá : Universidad de Ciencias Aplicadas y Ambientales 2019, 2019Co-Authors: Sánchez Barreto Jakelin, Ayala Blanco, Lucy StephaniaAbstract:60 páginas : gráficasEn Colombia una enfermedad huérfana es reconocida por la ley 1392 de 2010 y se define como aquella crónicamente debilitante, grave, que amenaza la vida y con una prevalencia menor de 1 por cada 5.000. Una de las enfermedades que se enfrentan a esta problemática es la Acromegalia y el Gigantismo debido a su complejidad en el diagnóstico, con una incidencia anual de tres a cuatro casos nuevos por millón de habitantes y prevalencia entre 40 y 90 casos por millón y dadas sus líneas de tratamiento se considera de alto costo. El desarrollo de nuevas tecnologías de salud en la actualidad permite generar una buena administración de recursos y fortalecer el sistema. Para realizar un análisis de impacto en presupuesto de alguna tecnología de interés es preciso gestionar las evaluaciones económicas las cuales permitirán apoyar en la toma de decisiones en salud a nivel mundial. En Colombia se encuentran reportadas 1483 personas que son diagnosticados con las patologías de acromegalia y Gigantismo. Los análogos de somatostatina han sido estudiados en el tratamiento de la acromegalia y Gigantismo, se ha evidenciado que son altamente eficaces en la inhibición de producción de la hormona de crecimiento. De acuerdo con las guías consultadas su efecto y la duración de su acción es mucho mayor en comparación a los agonistas dopaminérgicos como se evidencia en los rangos y periodos de dosificación anteriormente descritos, ya que se requiere una cantidad mucho mayor de Bromocriptina en periodos más cortos de tiempo. Para los costos del Pasireotide se evidencia que no hay un precio máximo o mínimo estandarizado ya que el promedio de los datos obtenidos a través del canal institucional en la base de datos del SISMED, muestra que el precio de todos los proveedores esta promediado y no hay un sobrecosto por parte de algún fabricante. El uso de estas tecnologías permite un abordaje de casos donde la acromegalia es altamente activa y no se puede controlar y que a su vez puedan ser utilizados en el tratamiento donde la alteración de la secreción de hormona de crecimiento es mínima. Para el FOSYGA el resultado obtenido permite evidenciar que si se aplica el escenario 1 a nivel determinístico habrá un ahorro de cerca de $10.000.000 COP, en un escenario número 2, la inversión debe ser de alrededor de $600.000 COP, pero es necesario por parte del estado tener en cuenta que la efectividad del tratamiento al implementar el uso de las tres nuevas tecnologías será mucho mayor. Se sugiere que las tecnologías denominadas (Octreotide, Lanreotide y Pasireotide) sean incluidas en el plan integral de salud, dado que el costo hace que sea accesible a la población.In Colombia a disease orphan is recognized by law 1392 of 2010 and is defined as that chronically debilitating, serious, that threatens the life and with a lower prevalence of 1 per 5,000. One of the diseases that are facing this problem is the acromegaly and Gigantism due to their complexity in the diagnosis, with an annual incidence of three to four new cases per million inhabitants and prevalence between 40 and 90 cases per million and given its lines of treatment is considered of high cost. The development of new health technologies today allows to generate good resource management and strengthen the system. To carry out a budget impact analysis of some technology of interest it is necessary To manage the economic evaluations which will allow to support in the decision making in health worldwide. In Colombia, 1483 people are reported to be diagnosed with the pathologies of acromegaly and Gigantism. Somatostatin analogues have been studied in the treatment of acromegaly and Gigantism, it has been shown that they are highly effective in inhibiting growth hormone production. According to the guides consulted their effect and the duration of their action is much greater compared to the dopamine agonists as evidenced in the ranges and periods of dosage described above, as it requires a much greater amount of Bromocriptine in shorter periods of time. For the costs of Pasireotide is evidence that there is a maximum price or minimum standardized as the average of the data obtained through the institutional channel in the database of the SISMED, shows that the price of all suppliers this averaging and there is no overrun by any manufacturer. The use of these technologies allows an approach of cases where acromegaly is highly active and cannot be controlled and which in turn can be used in the treatment where the alteration of the growth hormone secretion is minimal. For the FOSYGA the result obtained makes it clear that if scenario 1 is applied to the deterministic level there will be a saving of about $10 million COP, in scenario number 2, the investment must be of about $600,000 COP, but it is necessary by the state Keep in mind that the effectiveness of the treatment in implementing the use of the three new technologies will be much greater. It is suggested that the technologies called (Octeotride, lanreotide and pasireotide) are included in the comprehensive plan of health, given that the cost makes it accessible to the populationIncluye bibliografí
Marc Tollis - One of the best experts on this subject based on the ideXlab platform.
-
return to the sea get huge beat cancer an analysis of cetacean genomes including an assembly for the humpback whale megaptera novaeangliae
Molecular Biology and Evolution, 2019Co-Authors: Marc Tollis, Jooke Robbins, Andrew E Webb, Lukas F K Kuderna, Aleah F Caulin, Jacinda D Garcia, Martine Berube, Nader Pourmand, Tomas MarquesbonetAbstract:Cetaceans are a clade of highly specialized aquatic mammals that include the largest animals that have ever lived. The largest whales can have ∼1,000× more cells than a human, with long lifespans, leaving them theoretically susceptible to cancer. However, large-bodied and long-lived animals do not suffer higher risks of cancer mortality than humans-an observation known as Peto's Paradox. To investigate the genomic bases of Gigantism and other cetacean adaptations, we generated a de novo genome assembly for the humpback whale (Megaptera novaeangliae) and incorporated the genomes of ten cetacean species in a comparative analysis. We found further evidence that rorquals (family Balaenopteridae) radiated during the Miocene or earlier, and inferred that perturbations in abundance and/or the interocean connectivity of North Atlantic humpback whale populations likely occurred throughout the Pleistocene. Our comparative genomic results suggest that the evolution of cetacean Gigantism was accompanied by strong selection on pathways that are directly linked to cancer. Large segmental duplications in whale genomes contained genes controlling the apoptotic pathway, and genes inferred to be under accelerated evolution and positive selection in cetaceans were enriched for biological processes such as cell cycle checkpoint, cell signaling, and proliferation. We also inferred positive selection on genes controlling the mammalian appendicular and cranial skeletal elements in the cetacean lineage, which are relevant to extensive anatomical changes during cetacean evolution. Genomic analyses shed light on the molecular mechanisms underlying cetacean traits, including Gigantism, and will contribute to the development of future targets for human cancer therapies.
Fabien Aubret - One of the best experts on this subject based on the ideXlab platform.
-
genetic differentiation predicts body size divergence between island and mainland populations of common wall lizards podarcis muralis
Biological Journal of The Linnean Society, 2019Co-Authors: Geoffrey M. While, Tobias Uller, Sozos Michaelides, Hanna Laakkonen, Aurelie Coulon, Fabien AubretAbstract:Small-bodied vertebrates sometimes evolve Gigantism on islands, but there is a lack of consistent association with ecological factors or island characteristics. One possible reason is that, even if the ecological conditions are right, body size might fail to diverge on islands that were isolated recently or if there is gene flow between islands and the mainland. We studied body size, ventral colour polymorphism and genetic structure across nine islands and adjacent mainland populations of common wall lizards (Podarcis muralis) off the western coast of France. Population genetic data suggested that island populations might have maintained gene flow after their geographical isolation from the mainland. Island lizards were larger and heavier than mainland lizards on average, but the extent of Gigantism varied substantially between islands. Island size and distance from the mainland were poor predictors of body size, but lizards from populations that were highly genetically differentiated from the mainland were larger than lizards from less differentiated populations. Colour morphs that were rare on the mainland tended to be more common on islands. We propose that genetic isolation or bottlenecks promote body size evolution in island lizards, which makes it challenging to identify ecological causes of island Gigantism without complementary genetic information.
Aurelie Coulon - One of the best experts on this subject based on the ideXlab platform.
-
genetic differentiation predicts body size divergence between island and mainland populations of common wall lizards podarcis muralis
Biological Journal of The Linnean Society, 2019Co-Authors: Geoffrey M. While, Tobias Uller, Sozos Michaelides, Hanna Laakkonen, Aurelie Coulon, Fabien AubretAbstract:Small-bodied vertebrates sometimes evolve Gigantism on islands, but there is a lack of consistent association with ecological factors or island characteristics. One possible reason is that, even if the ecological conditions are right, body size might fail to diverge on islands that were isolated recently or if there is gene flow between islands and the mainland. We studied body size, ventral colour polymorphism and genetic structure across nine islands and adjacent mainland populations of common wall lizards (Podarcis muralis) off the western coast of France. Population genetic data suggested that island populations might have maintained gene flow after their geographical isolation from the mainland. Island lizards were larger and heavier than mainland lizards on average, but the extent of Gigantism varied substantially between islands. Island size and distance from the mainland were poor predictors of body size, but lizards from populations that were highly genetically differentiated from the mainland were larger than lizards from less differentiated populations. Colour morphs that were rare on the mainland tended to be more common on islands. We propose that genetic isolation or bottlenecks promote body size evolution in island lizards, which makes it challenging to identify ecological causes of island Gigantism without complementary genetic information.